Related references
Note: Only part of the references are listed.A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Hanne Haahr et al.
CLINICAL PHARMACOKINETICS (2014)
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Jane L. Chiang et al.
DIABETES CARE (2014)
Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial
M. J. Davies et al.
DIABETES OBESITY & METABOLISM (2014)
Assessment and monitoring of glycemic control in children and adolescents with diabetes
Marian J. Rewers et al.
PEDIATRIC DIABETES (2014)
Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes
Torben Biester et al.
PEDIATRIC DIABETES (2014)
Diabetic ketoacidosis and hyperglycemic hyperosmolar state
Joseph I. Wolfsdorf et al.
PEDIATRIC DIABETES (2014)
The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
Luigi Meneghini et al.
DIABETES CARE (2013)
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial
B. W. Bode et al.
DIABETIC MEDICINE (2013)
Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes ( BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
Chantal Mathieu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
Elizabeth R. Seaquist et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
T. Heise et al.
DIABETES OBESITY & METABOLISM (2012)
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
Alan J. Garber et al.
LANCET (2012)
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
Simon Heller et al.
LANCET (2012)
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Ib Jonassen et al.
PHARMACEUTICAL RESEARCH (2012)
Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 Diabetes Assessment of Detemir Administration in a Progressive Treat-To-Target Trial (ADAPT)
Jean-Pierre Le Floch et al.
DIABETES CARE (2009)
Assessment and management of hypoglycemia in children and adolescents with diabetes
William Clarke et al.
PEDIATRIC DIABETES (2009)
Refining basal insulin therapy: what have we learned in the age of analogues?
J. H. DeVries et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2007)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
DM Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes
RE Davis et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products
AR Mire-Sluis et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Predictors of acute complications in children with type 1 diabetes
A Rewers et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes
A Lindholm et al.
DIABETES CARE (2002)
Share Paper
